• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定垂体大腺瘤中的突变型 K-RAS。

Identification of mutant K-RAS in pituitary macroadenoma.

机构信息

Laboratório de Biomedicina do Cérebro, Instituto Estadual do Cérebro Paulo Niemeyer, Rua do Rezende156-Centro, Rio de Janeiro, 20231-092, Brazil.

Neurosurgery Division, Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil.

出版信息

Pituitary. 2021 Oct;24(5):746-753. doi: 10.1007/s11102-021-01151-6. Epub 2021 May 5.

DOI:10.1007/s11102-021-01151-6
PMID:33954928
Abstract

PURPOSE

RAS genes are among the most frequently mutated genes in cancer, where their mutation frequency varies according to the distinct RAS isoforms and tumour types. Despite occurring more prevalent in malignant tumours, RAS mutations were also observed in few benign tumours. Pituitary adenomas are examples of benign tumours which vary in size and aggressiveness. The present study was performed to investigate, via liquid biopsy and tissue analysis, the presence of K-RAS mutations in a pituitary macroadenoma.

METHODS

Molecular analysis was performed to investigate K-RAS mutations using the droplet digital PCR (ddPCR) method by evaluating both plasma (liquid biopsy) and the solid tumour of a patient diagnosed with a giant clinically non-functioning pituitary tumour.

RESULTS

The patient underwent surgical resection due to visual loss, and the histopathological analysis showed a gonadotrophic pituitary macroadenoma. The molecular analysis revealed the presence of mutant K-RAS both in the plasma and in the tumour tissue which, to our knowledge, has not been previously reported in the literature.

CONCLUSION

Our findings highlight the exceptional capacity of the digital PCR in detecting low frequency mutations (below 1%), since we detected, for the first time, K-RAS mutations in pituitary macroadenoma. The potential impact of K-RAS mutations in these tumours should be further investigated.

摘要

目的

RAS 基因是癌症中最常发生突变的基因之一,其突变频率根据不同的 RAS 同工型和肿瘤类型而有所不同。尽管 RAS 突变在恶性肿瘤中更为常见,但在少数良性肿瘤中也观察到 RAS 突变。垂体腺瘤就是大小和侵袭性不同的良性肿瘤的一个例子。本研究通过液体活检和组织分析,旨在调查一种垂体大腺瘤中 K-RAS 突变的存在情况。

方法

采用液滴数字 PCR(ddPCR)方法对 K-RAS 突变进行分子分析,通过评估患有巨大无功能性临床垂体肿瘤的患者的血浆(液体活检)和实体瘤,对 K-RAS 突变进行评估。

结果

该患者因视力丧失而接受了手术切除,组织病理学分析显示为促性腺激素垂体大腺瘤。分子分析显示,无论是在血浆中还是在肿瘤组织中,都存在 K-RAS 突变,据我们所知,这在文献中尚未有过报道。

结论

我们的研究结果强调了数字 PCR 检测低频突变(低于 1%)的卓越能力,因为我们首次在垂体大腺瘤中检测到 K-RAS 突变。应该进一步研究 K-RAS 突变对这些肿瘤的潜在影响。

相似文献

1
Identification of mutant K-RAS in pituitary macroadenoma.鉴定垂体大腺瘤中的突变型 K-RAS。
Pituitary. 2021 Oct;24(5):746-753. doi: 10.1007/s11102-021-01151-6. Epub 2021 May 5.
2
The pro-apoptotic K-Ras 4A proto-oncoprotein does not affect tumorigenesis in the ApcMin/+ mouse small intestine.促凋亡的K-Ras 4A原癌蛋白不影响ApcMin/+小鼠小肠的肿瘤发生。
BMC Gastroenterol. 2008 Jun 13;8:24. doi: 10.1186/1471-230X-8-24.
3
Molecular screening of pituitary adenomas for gene mutations and rearrangements.垂体腺瘤的基因突变和重排的分子筛查。
J Clin Endocrinol Metab. 1993 Jul;77(1):50-5. doi: 10.1210/jcem.77.1.8100831.
4
Ras mutations in human pituitary tumors.人类垂体肿瘤中的Ras突变。
J Clin Endocrinol Metab. 1992 Apr;74(4):914-9. doi: 10.1210/jcem.74.4.1312542.
5
K-ras exon 4A has a tumour suppressor effect on carcinogen-induced murine colonic adenoma formation.K-ras 外显子 4A 对致癌物诱导的小鼠结肠腺瘤形成具有肿瘤抑制作用。
J Pathol. 2010 Apr;220(5):542-50. doi: 10.1002/path.2672.
6
Molecular screening for somatic mutations in corticotropic adenomas of dogs with pituitary-dependent hyperadrenocorticism.垂体依赖性肾上腺皮质功能亢进犬促肾上腺皮质激素腺瘤体细胞突变的分子筛查。
J Endocrinol Invest. 1997 Jan;20(1):1-7. doi: 10.1007/BF03347964.
7
H-ras mutations in human pituitary carcinoma metastases.人垂体癌转移灶中的H-ras基因突变
J Clin Endocrinol Metab. 1994 Apr;78(4):842-6. doi: 10.1210/jcem.78.4.8157709.
8
Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features.结直肠肿瘤中Ras信号通路的遗传和表观遗传改变:基于肿瘤临床病理特征的分析
Br J Cancer. 2007 Nov 19;97(10):1425-31. doi: 10.1038/sj.bjc.6604014. Epub 2007 Oct 9.
9
Genetic heterogeneity of the c-K-ras locus in colorectal adenomas but not in adenocarcinomas.结直肠腺瘤中c-K-ras基因座存在遗传异质性,而腺癌中则不存在。
J Natl Cancer Inst. 1993 Jul 7;85(13):1058-63. doi: 10.1093/jnci/85.13.1058.
10
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.液体活检中 RAS 检测与 CAPRI-GOIM 试验中接受一线 FOLFIRI 联合西妥昔单抗治疗的转移性结直肠癌患者的结局相关。
Ann Oncol. 2018 Jan 1;29(1):112-118. doi: 10.1093/annonc/mdx417.

引用本文的文献

1
The Role of RAS in CNS Tumors: A Key Player or an Overlooked Oncogene?RAS在中枢神经系统肿瘤中的作用:关键角色还是被忽视的致癌基因?
Int J Mol Sci. 2025 Apr 25;26(9):4104. doi: 10.3390/ijms26094104.
2
Clinical insights into circulating free-DNA in patients with bone sarcomas and ewing sarcoma.骨肉瘤和尤因肉瘤患者循环游离DNA的临床见解。
Clinics (Sao Paulo). 2025 Apr 26;80:100661. doi: 10.1016/j.clinsp.2025.100661. eCollection 2025.
3
Mechanism-Based Redesign of GAP to Activate Oncogenic Ras.基于机制的 GAP 重设计以激活致癌 Ras。

本文引用的文献

1
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.美国 2012-2016 年诊断的原发性脑和其他中枢神经系统肿瘤 CBTRUS 统计报告。
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100. doi: 10.1093/neuonc/noz150.
2
Applications of liquid biopsies for cancer.液体活检在癌症中的应用。
Sci Transl Med. 2019 Aug 28;11(507). doi: 10.1126/scitranslmed.aay1984.
3
KRAS mutations drive adenomatoid odontogenic tumor and are independent of clinicopathological features.KRAS 突变驱动腺泡状牙源性肿瘤发生,且与临床病理特征无关。
J Am Chem Soc. 2023 Sep 20;145(37):20302-20310. doi: 10.1021/jacs.3c04330. Epub 2023 Sep 8.
4
The Use of Liquid Biopsy in the Molecular Analysis of Plasma Compared to the Tumour Tissue from a Patient with Brain Metastasis: A Case Report.液体活检在血浆分子分析中的应用与脑转移瘤患者肿瘤组织的比较:病例报告。
Medicina (Kaunas). 2023 Feb 25;59(3):459. doi: 10.3390/medicina59030459.
5
Architects of Pituitary Tumour Growth.垂体肿瘤生长的建筑师。
Front Endocrinol (Lausanne). 2022 Jun 28;13:924942. doi: 10.3389/fendo.2022.924942. eCollection 2022.
6
Clinical Biology of the Pituitary Adenoma.垂体腺瘤的临床生物学。
Endocr Rev. 2022 Nov 25;43(6):1003-1037. doi: 10.1210/endrev/bnac010.
Mod Pathol. 2019 Jun;32(6):799-806. doi: 10.1038/s41379-018-0194-4. Epub 2019 Jan 14.
4
A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients.一项研究 K-RAS4A 和 K-RAS4B 剪接变异体在晚期非小细胞肺癌患者中表达的横断面研究。
Lung Cancer. 2018 Feb;116:7-14. doi: 10.1016/j.lungcan.2017.12.005. Epub 2017 Dec 11.
5
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.KRAS:胰腺癌的关键驱动因子和治疗靶点。
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):a031435. doi: 10.1101/cshperspect.a031435.
6
mutation in papillary fibroelastoma: a true cardiac neoplasm?乳头状纤维弹性瘤中的突变:一种真正的心脏肿瘤?
J Pathol Clin Res. 2017 Mar 7;3(2):100-104. doi: 10.1002/cjp2.66. eCollection 2017 Apr.
7
Low-frequency mutations are prevalent in lung adenocarcinomas.低频突变在肺腺癌中很常见。
Per Med. 2015 Mar;12(2):83-98. doi: 10.2217/pme.14.69.
8
Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer.结直肠癌中岩藻糖基化增加与转移潜能的关系。
J Natl Cancer Inst. 2016 Sep 14;108(9). doi: 10.1093/jnci/djw210. Print 2016 Sep.
9
Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery.对结直肠癌患者循环肿瘤细胞进行液滴数字PCR可在手术前预测KRAS突变。
Mol Oncol. 2016 Oct;10(8):1221-31. doi: 10.1016/j.molonc.2016.05.009. Epub 2016 Jun 7.
10
RAS isoforms and mutations in cancer at a glance.癌症中的RAS亚型与突变一览。
J Cell Sci. 2016 Apr 1;129(7):1287-92. doi: 10.1242/jcs.182873. Epub 2016 Mar 16.